{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Supermobilizers"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Normal Mobilizers"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Non mobilizers"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Number of participants able to collect equal to or more than 8 x 10\\^6 CD34+ cells/kg with addition of plerixafor to etoposide and filgrastim. These participants are defined as supermobilizers. Participants with less than 8 x 10\\^6 CD34+ cells/kg are defined as normal mobilizers.","groups":[{"description":"Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \\>= 8 x 10\\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\\< 2 x 10\\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.\n\nplerixafor: Given SC\n\nfilgrastim: Given SC\n\netoposide: Given IV\n\nleukapheresis: Undergo apheresis","id":"OG000","title":"Treatment (Stem Cell Supermobilization)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants that went on study","reportingStatus":"POSTED","timeFrame":"Within 2 days of apheresis","title":"Collection Using Plerixafor, Etoposide, and Filgrastim","type":"PRIMARY","unitOfMeasure":"Participants"}